Cantargia AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CANTA.ST research report →
Companywww.cantargia.com
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP.
- CEO
- Hilde Hermansen Steineger
- IPO
- 2015
- Employees
- 22
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $790.59M
- P/E
- 4.91
- P/S
- 2.49
- P/B
- 3.38
- EV/EBITDA
- 3.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.42%
- Op Margin
- 50.25%
- Net Margin
- 50.73%
- ROE
- 77.69%
- ROIC
- 67.79%
Growth & Income
- Revenue
- $316.70M · 0.00%
- Net Income
- $146.97M · 190.92%
- EPS
- $0.59 · 167.05%
- Op Income
- $154.39M
- FCF YoY
- 191.96%
Performance & Tape
- 52W High
- $6.59
- 52W Low
- $1.00
- 50D MA
- $3.85
- 200D MA
- $3.79
- Beta
- 2.08
- Avg Volume
- 1.64M
Get TickerSpark's AI analysis on CANTA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CANTA.ST Coverage
We haven't published any research on CANTA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CANTA.ST Report →